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Abstract 
The Scientist-Practitioner Model is a system of education used by many 
graduate programs in applied fields of psychology.  The goal of this educational 
model is to help clinicians and other practitioners to learn to use empirical 
research as a basis for the applied work that they do and also for them to learn to 
use the experience of applied clinical practice to guide research questions and to 
advance scientific thinking in the discipline of Psychology.  As a student who 
plans to pursue a Ph.D. in Clinical Psychology, I felt that it would be beneficial 
for me to experience the Scientist-Practitioner Model to gain a better understand 
of what it entails.  
In order to accomplish this goal, I have been participating in an internship 
as a mental-health assistant in a group home for adult males. All of the residents 
in this facility are afflicted with various psychiatric disorders; some experience 
concomitant mild intellectual deficiencies and substance-abuse problems as well. 
Outside of my internship, I have been investigating the topic of 
Schizophrenia, a diagnosis that is common among many of the residents with 
whom I am working. I am studying the epidemiological features of this disorder 
and its etiology, course, treatment and management, and prognosis.  By 
synthesizing this information with my direct experiences in working in the group 
home, I am developing researchable hypotheses about this disorder that ultimately 
can be empirically tested.  Thus, I am able to directly experience the Scientist-
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Practitioner Model, an exercise that I hope will help to better prepare me for my 
future graduate school experiences.  
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Exploring the Scientist-Practitioner Model in Clinical Psychology 
 
The scientist-practitioner model of education is a major program 
philosophy that forms the basis of many graduate programs in Clinical 
Psychology.  This model is used to help graduate students to learn how to 
integrate science with applied practice, that is, to participate in the process 
whereby science informs clinical practice and how clinical practice generates 
empirical research.  In the following literature review, the topic of Schizophrenia 
is discussed.  An historical background of the disorder is given and the origins of 
its name are described.  The DSM-IV-TR system of diagnosis is explained, a 
description of the subtypes of Schizophrenia is provided, and their classifications 
are explained.  The course and prognosis of the disorder are then explained.  Next, 
the literature review identifies different theories of the etiology of the disorder, 
including genetic and environmental explanations.  Neurological theories are also 
explained, including the dopamine theory, serotonin theory, glutamate theory, 
cavum septum pellucidi theory, and ventricle theory.  The literature review 
concludes with information about how Schizophrenia is managed with 
antipsychotic drugs and the possible side affects of those medications.   
 Next, a description of clinical experiences from an internship as a mental-
health assistant is provided.  It explains different symptoms experienced by clients 
at a group home in Rhode Island.  None of the information included in this section 
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contains any identifying information; residents' ages have been generalized to a 
range and no names have been included.   
 The final section includes different types of researchable hypotheses.  
These questions were developed using the scientist-practitioner model.  Here, 
experiences gained through my clinical work led to particular questions about 
Schizophrenia.  The questions that were developed could possibly be used in 
conducting a research study in the future. 
Review of Literature 
Schizophrenia is a psychotic disorder that, when diagnosed, comes with a 
stigma attached to it.  Many practitioners are reluctant to diagnose this disorder 
because of this and the fact that it is a difficult diagnosis to make due to the broad 
array of symptoms. Symptoms of the illness can be both positive and negative.  
Positive symptoms include those that can be treated with medications, such as 
hallucinations and delusions.  Negative symptoms are those that are extremely 
hard to treat such as flat or blunted affect.   
Historical Issues 
Emil Kraeplin was the first person to devise a way to classify psychosis 
(Taylor, 2006).  The first group of psychoses was dementia praecox, which means 
“senility of the young.”  This included “hebephrenia (a kind of childish insanity), 
catatonia, and dementia paranoids (paranoia), and was said to follow a chronic 
course” (Taylor, 2006, p. 3). The other classification was manic-depressive 
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insanity (Taylor, 2006).  Dementia praecox eventually became named 
“Schizophrenia” in 1911 by Eugen Bleuler because the meaning of dementia 
praecox was inaccurate.  Regardless of the name used to label this psychiatric 
disorder, it has been agreed upon that there is a biological aspect to it.  Today, the 
most common term for this disorder is Schizophrenia, but people must keep in 
mind that a psychiatric disorder does not define the individual who has it.  The 
individual is a person first, and afflicted with Schizophrenia second.  Thinking of 
the disorder this way can help to reduce the stigma associated with it.  
 Throughout history, different individuals have classified Schizophrenia 
with similar symptoms.  Freud explained the main symptoms of Schizophrenia as 
“thought disorder, blunting of affect (i.e. near-absent expressions of glee or 
sadness) and autism (essentially social withdrawal).  Hallucinations and delusions 
were considered not as core symptoms but as reactions to the disease itself” 
(Taylor, 2006, p. 3).  Schneider’s first rank criteria were used by most 
psychiatrists in Europe, and consisted of auditory hallucinations, thought insertion 
or withdrawal, thought broadcasting, passivity feelings, and primary delusions 
(Taylor, 2006).  Other psychiatrists all over the world had different definitions of 
what Schizophrenia was.  This showed that there was a need for a classification 
system.   
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Classification and Subtypes 
There are multiple classification systems for Schizophrenia, but all use 
similar descriptions.  The Diagnostic and Statistical Manual-IV-TR (APA, 2000), 
which is the most common classification system used, uses the following criteria: 
 
A disorder that lasts for at least 6 months and includes at 
least 1 month of active-phase symptoms (i.e., two or more 
of the following to be present for a significant portion of a 
one month period: delusions, hallucinations, disorganized 
speech, grossly disorganized or catatonic behavior, 
negative symptoms (p. 298).  There must be 
Social/Occupational dysfunction, disturbance must persist 
for at least six months, Schizoaffective and mood disorder 
exclusion, substance/general medical condition exclusion, 
and relationship to a pervasive developmental disorder.  If 
delusions are considered bizarre, then a diagnosis of 
Schizophrenia is appropriate without any other symptoms.  
The prevalence of Schizophrenia ranges from .05% to 1.5% 
among adults and the “annual incidences are most often in 
the range of 0.5 to 5.0 per 10,000” (p. 308).  “Median age 
of onset for the first psychotic episode of Schizophrenia is 
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in the early to mid-20s for men and in the late 20s for 
women” (p. 308).  “Rates of comorbidity with Substance-
Related Disorders are high.  Nicotine Dependence is 
especially high, with estimates ranging from 80% to 90% 
of individuals with Schizophrenia being regular cigarette 
smokers” (p. 304).  
 
 Schizophrenia is divided into different subtypes including paranoid type, 
disorganized type, catatonic type, undifferentiated type, and residual type.  
Paranoid type is “the presence of prominent delusions or auditory hallucinations 
in the context of a relative preservation of cognitive functioning and affect” 
(APA, 2000, p. 313).  Disorganized type is defined as “prominent disorganized 
speech, disorganized behavior, and flat or inappropriate behavior” (APA, 2000, p. 
314).  Catatonic type is “marked psychomotor disturbance that may involve 
motoric immobility, excessive motor activity, extreme negativism, mutism, 
peculiarities of voluntary movement, echolalia, or echopraxis” (APA, 2000, p. 
315.  Undifferentiated type is “the presence of symptoms that meet Criterion A of 
Schizophrenia but that do not meet criteria for the Paranoid, Disorganized or 
Catatonic type” (APA, 2000, p. 317).  Residual type is used “when there has been 
at least one episode of Schizophrenia, but the current clinical picture is without 
prominent positive psychotic symptoms” (APA, 2000, p. 317).  Schizophrenia is 
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not a homogeneous psychiatric disorder.  There are no two cases that are exactly 
alike.  The classification systems are extremely broad and two individuals with 
completely different symptoms may end up with the exact same diagnosis.  
Course and Prognosis 
Schizophrenia is generally diagnosed during early adulthood and tends to 
affect an individual for the rest of his or her life.  It is rare to see only one 
psychotic episode and then no symptoms following that episode.  According to 
Taylor (2006), “most cases of Schizophrenia are said to follow one of seven 
patterns, which can be condensed into three broad outcomes: (1) continuous 
course (no relapses or remissions); (2) undulating course (relapses with or without 
residual symptoms in remissions); and (3) atypical course (various types but 
including long-term improvement after continuous course)”  (p. 8).   
This disorder, however, can be managed with different types of 
treatments.  These treatments include the use of antipsychotic drugs.  In the past, 
antipsychotic drugs had many side affects similar to those of sedatives.  Today, 
pharmacology has come a long way to produce drugs that allow people to lead as 
normal lives as possible.  This is a huge step for individuals with Schizophrenia 
because this gives them the opportunity to make a life for themselves if possible.  
Today there are many different types of antipsychotic drugs, and the combinations 
of drugs used differ on a case to case basis. 
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Etiology 
It is not completely clear as to what actually causes Schizophrenia.  Some 
researchers suggest that complications during pregnancy or birth can affect the 
probability of becoming diagnosed with Schizophrenia in the future.  There has 
been a higher correlation between people being born in winter months and 
becoming diagnosed with Schizophrenia as opposed to those who are born in the 
summer months.  This is thought to be a result of illness of the mother during 
pregnancy (Taylor, 2006).  Genetics are said to be a major reason for the 
development of Schizophrenia.  “The lifetime risk of Schizophrenia is around 1%; 
in people born to parents who both have a diagnosis of Schizophrenia the lifetime 
risk approaches 50%” (p. 14), and it is more common to see both identical twins 
with Schizophrenia than to see both fraternal twins with Schizophrenia (Taylor, 
2006).  These differences are extreme, giving researchers evidence to support a 
genetic theory.   
Environment may also play a role in the development of Schizophrenia.  
According to Taylor (2006), environmental factors are likely to play a role in the 
development and progression of this illness and it has been determined that “60% 
of all those diagnosed with Schizophrenia have no first or second-degree relatives 
with the condition” (p. 14).  
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 There are many different theories behind schizophrenia and the brains 
involvement with the illness.  One theory is the dopamine theory, which “suggests 
that the positive symptoms of schizophrenia are caused by overactivity of 
synapses between dopaminergic neurons of the ventral tegmental area and 
neurons in the nucleus accumbens and amygdala” (Carlson, 2007, p. 554).  One of 
the first drugs discovered that helps dramatically in the treatment of 
Schizophrenia is chlorpromazine.  It significantly decreased positive symptoms in 
patients with Schizophrenia and it decreased the amount of time spent in hospitals 
for patients with this illness (Carlson, 2007).  Many drugs have since been 
developed, all of which block dopamine receptors also known as dopamine 
antagonists.  Drugs that are dopamine agonists support this dopamine theory of 
Schizophrenia as well.  When individuals participate in the use of drugs such as 
amphetamines, cocaine, methylphenidate (all block dopamine reuptake), and L-
DOPA (produces more dopamine), symptoms can occur which mimic those 
psychotic symptoms of Schizophrenia and these symptoms produced by these 
drugs can be relieved with antipsychotic drugs (Carlson, 2007).  While the 
dopamine theory does explain the positive symptoms of Schizophrenia, it does not 
explain the negative symptoms which present similar to those of brain damage 
(Carlson, 2007).     
  Some evidence against the dopamine theory is the failure of antipsychotics 
that are dopamine antagonists (Taylor, 2006).  The success of clozapine works 
Exploring the Scientist Practitioner Model           12
against the dopamine theory because it has low dopamine receptor occupancy and 
this suggests that there might be other transmitters in the brain involved in 
schizophrenia (Williamson, 2006).  Even though clozapine does work against the 
dopamine theory because it is a low dopamine receptor, it does not work 
completely against it because it is still somewhat of a dopamine antagonist.  All 
anti-psychotics that are currently prescribed are some sort of a dopamine 
antagonist (Taylor, 2006).  However, anti-psychotics that are D2 receptor 
antagonists show the most support for the dopamine theory (Taylor, 2006).   
It is thought that the serotonergic system might also be involved in 
schizophrenia, specifically the 5HT2A receptor and most of the newer anti-
psychotics have 5HT2A antagonist activity (Taylor, 2006). This theory might 
explain why clozapine, ziprasidone, risperidone, quetiapine, and olanzapine are 
successful in the treatment of schizophrenia (Meltzer, et al., 2003), however 
serotonin is closely related to dopamine which could also support the reasons for 
clozapine’s success (Taylor, 2006).  Serotonin agonists, along with dopamine 
agonists, can cause psychotic symptoms and this supports both the serotonin and 
dopamine theories of schizophrenia.   
Glutamate, an amino acid, may also play a role in schizophrenia.  
Glutamate “appears both to stimulate and inhibit dopamine release, depending on 
the conditions and location.  Cerebrospinal fluid glutamate levels may be altered 
in people with schizophrenia (Taylor, 2006 p. 25).”  The glutamate theory was 
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based off a clinical observation of chronic abusers of NMDA receptor antagonist 
phencyclidine (PCP) (Paz, et al., 2008).  Dopamine, serotonin, and glutamate are 
included in the major theories behind schizophrenia and the role that the brain 
plays in the illness.   
 “An increased incidence of large cavum septum pellucidi has been 
demonstrated in individuals with Schizophrenia.  This may have important 
pathophysiological implication, because it is suggestive of an early (i.e. prenatal) 
midline developmental brain abnormality , at least in a subgroup of individuals 
with schizophrenia” (APA, 2000, p. 305).  Septum pellucidi is located underneath 
the corpus callosum and “It is believed to be a relay station in the limbic system 
connecting the hypothalamic autonomic system to hippocampus, amygdala, 
habenula and brain-stem reticular formation” (Rajarethinam, et al., 2008, p. 22).  
There is sometimes a cavity between the septum pellucidi and this is called the 
cavum septum pellucidi, which is filled with cerebrospinal fluid and is sometimes 
referred to as the 5th ventricle.  This is present at birth in all humans; however it 
does close up by the age of 3 in most people.  It has been observed that this is 
present in individuals with schizophrenia, supporting a biological reason for 
causes of Schizophrenia.   
 More neurological evidence for the causes of Schizophrenia is loss of 
brain tissue and enlarged ventricles in the brain.  “In the Structural neuroimaging 
literature, the most widely studied and most consistently replicated finding 
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continues to be enlargement of the lateral ventricles” (APA, 2000, p. 305).   
“Many studies have also demonstrated decreased brain tissue as evidence by 
widened cortical sulci and decreased volumes of gay and white matter” (APA, 
2000, p. 305).  Ventricles are spaces deep within the brain and if the spaces are 
larger than in a normal brain, then the mass of the actual tissue in the brain has to 
be less in patients with Schizophrenia.  “In fact, Hulshoff-Pol et al. (2002), foud 
that although every one loses some cerebral gray matter as they age, the rate of 
tissue loss is greater in schizophrenic patients” (Carlson, 2007).   
Pharmacological Management 
Antipsychotics are defined as “drugs used in the treatment of psychotic 
disorders that help alleviate hallucinations and delusional thinking” (Nevid, 2009, 
p. 582).  There are many different types of antipsychotic drugs which fall into the 
two categories of typical antipsychotic drugs and atypical antipsychotic drugs.  
Typical antipsychotic drugs are older medications that tend to have more side 
effects than atypical antipsychotic drugs.  “The first class of antipsychotic drugs 
were phenothiazines, which included the drugs Thorazine (chlorpromazine) and 
Mellaril (thioridazine)” (Nevid, 2009, p. 582).  These typical antipsychotics also 
include Trifluoperazine (stelazine), Fluphenazine (Prolisin) and others, whose 
side effects include “movement disorders, drowsiness, restlessness, dry mouth, 
blurred vision, and muscle rigidity” (Nevid, 2009, p. 585).  These drugs surfaced 
in the 1950’s and were the first step in controlling hallucinations and delusions.  
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Today, however, Mellaril (thioridazine) is “indicated for the management of 
schizophrenic patients who fail to respond adequately to treatment with other 
antipsychotic drugs.  Due to the risk of significant, potentially life threatening, 
proarrhythmic effects with thioridazine treatment, thioridazine should be used 
only in patients who have failed to respond adequately to treatment with 
appropriate courses of other antipsychotic drugs, either because of insufficient 
effectiveness or the inability to achieve an effective dose use to intolerable 
adverse effects form those drugs” (Physicians desk reference, 2009, p. 2195-6).  
This is common to see with older medications.  The newer atypical antipsychotic 
drugs include clozapine, risperidone, olanzapine and others.  These newer drugs 
are just as effective as the previous typical antipsychotic drugs but tend to have 
fewer side effects.  However, there are still concerns for side effects with the 
newer antipsychotic drugs.  For example, the side effects of clozapine (clozaril) 
can include “potentially lethal blood disorder, seizures, fast heart rate, drowsiness, 
dizziness, nausea” (Nevid, 2009, p. 585).  These side effects should be monitored 
closely.         
A major possible side effect of older typical antipsychotic drugs is tardive 
dyskinesia.  “Tardive dyskinesia (TD) is a painful and disfiguring motor side 
effect of long-term anti-psychotic use. TD presents months or years after initiation 
of anti-psychotic treatment, persists after drug withdrawal and may be irreversible 
(Bishnoi, et al., 2008).”  Symptoms of tardive dyskinesia present themselves very 
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similarly to Parkinson’s disease, leading researchers to suspect that Schizophrenia 
is the opposite of Parkinson’s disease.  Antipsychotic drugs taken for the 
treatment of Schizophrenia cause symptoms of Parkinson’s disease, and L-DOPA 
taken in the treatment of Parkinson’s disease causes psychotic symptoms present 
in Schizophrenia (Carlson, 2007).  Atypical anti-psychotic drugs have less of a 
chance of causing tardive dyskinesia than do the older typical anti-psychotic 
drugs.   
Applied Clinical Experience 
For the past semester, I have been serving an internship as a Mental-
Health Assistant at a group home in Rhode Island.  All of the clients who live in 
the home are men over the age of 18 and have been diagnosed with severe 
psychiatric disorders; many also have substance-abuse problems and intellectual 
disabilities.  Through my clinical experience, I have had the opportunity to 
observe the effects of mental disorders, the courses of those disorders, and how 
they affect the individuals afflicted with them.   
There have been many hospitalizations of the clients during my time at the 
group home.  Sometimes the hospitalizations are a result of medication refusals.  
Most of the clients are overweight and some have diabetes.  Many of the weight-
gain issues for the clients are a result of the medications that they are taking.  For 
example, Clozaril (a drug used in the management of Schizophrenia) often leads 
to extreme weight gain.  If insulin is not taken within a 24 hour time period, then 
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hospitalization may be required.  Hospitalization also is required if staff members 
feel threatened by a client or if a client discloses that he is afraid of hurting 
himself or someone else.      
I have seen that it is hard to motivate the clients to exercise and to eat 
healthy diets.  Although the meals that are cooked for them are part of a balanced 
diet, clients are free to spend their money on what they choose, and much of their 
money is spent on junk food.  The clients also have trouble with completing oral- 
and physical-hygiene tasks.  Many of them do not shower on a regular basis.   
Almost all of the clients at the group home smoke cigarettes and have a 
history of some sort of substance abuse.  I have found that substance-abuse 
problems are common among individuals with Schizophrenia; however, research 
has not determined if the substance use is a result of the symptoms or if the illness 
can be caused from substance use possibly as a part of a diathesis-stress model.  
Client Examples   
 When I first started my internship, I had the opportunity to see how the 
group home receives new clients.  A new client in his early 20s was coming to 
live at the home during the first month that I was there.  When he arrived, I went 
with him and his counselor to an intake meeting with the social worker.  She 
asked him about his background, but this client had difficulty reporting accurately 
on his history.  I was able to see that getting information from clients can be 
difficult at times.  The social worker asked him to describe his symptoms.  This 
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particular client is diagnosed with both Schizophrenia and an intellectual 
disability.  He reports that he hears multiple voices that argue with each other and 
himself.  He tries to negotiate with the voices in order to calm them down, but that 
has not been effective.  One of the voices dominates the others and commands 
him to engage in activities in order to avoid harm or death.  Recently, he has had a 
medication change for psychoses.  This same medication has helped other clients 
in the group home as well, and it has helped to calm the voices that this client 
reports hearing.  In the past, no medications had worked to calm the voices so this 
has been a marked improvement for this client.  Already, I have noticed that it is 
much easier to have a conversation with him and that he is able to better follow 
the conversation and not go off on tangents.   
 Another client has given me the opportunity to see how the illness spirals 
up and down.  This client is an older male in his late 60s.  When I first came to the 
home, he was quiet and didn’t speak much.  During the past three months, 
however, he has been on a spiral downward into another cycle of Schizophrenia.  
His voice has become high pitched and giddy; he tends to giggle a lot.  He is 
hypersexual and can often be found talking to an imaginary person.  This appears 
to be a hallucination.  He also has grandiose delusions and paranoia.   
Common Symptoms 
Paranoia tends to be a common symptom among the clients who live in 
the house.  Some of the clients believe that people or the members of the Central 
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Intelligence Agency (CIA) are pursuing them or that the people in the cars driving 
by are inserting their thoughts into the client’s heads.  Many of the clients also 
tend to fixate on objects or possessions, for example, their money and their money 
ledgers.  Clients often ask their counselors to review their ledgers and budgets 
with them.  One day, I observed a client ask the counselor about his ledger over 
five times.   
Flat affect is a negative symptom of Schizophrenia that is hard to 
understand until one has a chance to observe it.  Some of the clients have this 
negative symptom and show barely any emotion.  It is rare to see these 
individuals laugh or even smile, and they react to everything in the same manner.        
Another client, in his 40s, appears to be depressed and bored with his life.  
I think this is common among many of the clients because living in the group 
home there is not too much excitement.  Every day seems to be almost identically 
scheduled, unless there is a doctor’s appointment or a different type of 
appointment.  This client tries to capture the attention of the counselors in the 
house for his own entertainment.  For example, he might refuse medication, start 
arguments, and refuse to go to activities or day programs.  I think that this is 
because there is no change in his day to day life and he is bored and depressed 
with his living situation.  He frequently threatens to move out to see how the 
counselors will react to his threats.  If his threats are ignored by the counselors, 
however, he tends to let them go.     
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Researchable Hypotheses 
After my experience at the group home and researching Schizophrenia I 
have come up with some researchable hypotheses.  I am curious as to why so 
many people with Schizophrenia smoke cigarettes.  Almost all of the clients at the 
group home smoke at least a pack of cigarettes a day; according to the literature 
on Schizophrenia my observation has been supported by the DSM-IV-TR (APA, 
2000) that concludes that 80-90% of individuals with Schizophrenia smoke 
cigarettes.  I would like to look at whether these individuals with the disorder 
smoke because of a reaction with their symptoms and, specifically, whether 
smoking calms the symptoms (e.g., auditory hallucinations) of the disorder.   
I have also noticed through my internship that individuals with 
Schizophrenia tend to have a history of substance abuse.  I would like to look at 
whether people with the disorder use drugs because of their symptoms or if drug 
use is part of a diathesis-stress model responsible for causing Schizophrenia.  
Last, but not least, I would like to look at why so many individuals with 
Schizophrenia have multiple diagnoses, for example Substance Abuse Disorder, 
Intellectual Disability, and Depression.   
Conclusion 
This project has been an amazing experience.  It has given me the 
opportunity to experience the scientist-practitioner model and to realize that I 
have chosen the right education path, being that I want to pursue a Ph.D. in 
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Clinical Psychology.  Interning at the group home has given me a chance to see 
which mental disorders spark my interest.  I have learned that Schizophrenia and 
Substance Abuse are two areas that are of high interest to me.   
Some limitations of the project include the short period of time that it had 
to be completed in (one semester) and the amount of time spent at the group 
home.  If someone were to repeat this project, I would recommend that it should 
be done over a full year period and that they should spend more than eight hours a 
week at the facility.  Over all, I am extremely thankful for having the opportunity 
to complete a project of this type.  Without this project I would have no clinical 
experience that let me know that I have chosen the correct career path for me.     
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